Ceftazidime Poloxamer Gel: Expanding the Therapeutic Armamentarium for Ciprofloxacin-Resistant Pseudomonas Mastoid Cavity Otorrhea.
Otol Neurotol
; 45(6): e490-e493, 2024 Jul 01.
Article
in En
| MEDLINE
| ID: mdl-38773842
ABSTRACT
OBJECTIVE:
To present and evaluate the treatment of ciprofloxacin-resistant Pseudomonas mastoid cavity otorrhea with a ceftazidime thermosensitive poloxamer gel. STUDYDESIGN:
A retrospective clinical capsule report. PATIENTS Three patients diagnosed with ciprofloxacin-resistant Pseudomonas otorrhea in the setting of a previous canal-wall-down mastoidectomy between March 2019 and June 2023 visiting our tertiary care institution were retrospectively reviewed. INTERVENTION Application of a 2% ceftazidime thermosensitive poloxamer gel to mastoid cavity. MAIN OUTCOMEMEASURES:
No evidence of disease during microscopic inspection of the ear within a month of initial treatment or bacterial eradication on subsequent culture.RESULTS:
Two patients had complete resolution of symptoms and achieved a safe and dry ear after topical application of the hydrogel. The second patient had pseudomonal eradication on culture, but persistent otorrhea due to other multidrug-resistant bacteria and an anatomically unfavorable mastoid cavity, which ultimately resolved after revision surgery.CONCLUSIONS:
This small case series suggests that topical treatment of mastoid cavity otorrhea with a 2% ceftazidime poloxomer gel is a potential therapeutic avenue in patients with ciprofloxacin-resistant Pseudomonas .
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pseudomonas Infections
/
Ciprofloxacin
/
Ceftazidime
/
Poloxamer
/
Gels
/
Anti-Bacterial Agents
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Otol Neurotol
Journal subject:
NEUROLOGIA
/
OTORRINOLARINGOLOGIA
Year:
2024
Document type:
Article
Affiliation country: